{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:08:21Z","timestamp":1793178501726,"version":"4.5.0"},"reference-count":314,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,1]]},"DOI":"10.1210\/er.2012-1008","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T13:48:16Z","timestamp":1365169696000},"page":"171-208","source":"Crossref","is-referenced-by-count":397,"title":["Progestogens Used in Postmenopausal Hormone Therapy: Differences in Their Pharmacological Properties, Intracellular Actions, and Clinical Effects"],"prefix":"10.1210","volume":"34","author":[{"given":"Frank Z.","family":"Stanczyk","sequence":"first","affiliation":[{"name":"Departments of Obstetrics and Gynecology (F.Z.S., S.W., D.R.M.) Los Angeles, California, 90033"},{"name":"Preventive Medicine (F.Z.S.), University of Southern California Keck School of Medicine, Los Angeles, California, 90033;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet P.","family":"Hapgood","sequence":"additional","affiliation":[{"name":"Departments of Obstetrics and Gynecology (F.Z.S., S.W., D.R.M.) Los Angeles, California, 90033"},{"name":"Department of Molecular and Cell Biology (J.H.), University of Cape Town, Private Bag, Rondebosch 7700, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Winer","sequence":"additional","affiliation":[{"name":"Departments of Obstetrics and Gynecology (F.Z.S., S.W., D.R.M.) Los Angeles, California, 90033"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Daniel R.","family":"Mishell","sequence":"additional","affiliation":[{"name":"Departments of Obstetrics and Gynecology (F.Z.S., S.W., D.R.M.) Los Angeles, California, 90033"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"key":"2019041122345660900_B1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"2019041122345660900_B2","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"2019041122345660900_B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0010-7824(01)00222-0","article-title":"Use of the name \u201cProgestin.\u201d","volume":"64","author":"Stanczyk","year":"2001","journal-title":"Contraception"},{"key":"2019041122345660900_B4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00042192-200310020-00003","article-title":"Role of progestogen in hormone therapy for postmenopausal women: position statement of the North American Menopause Society","volume":"10","author":"North American Menopause Society","year":"2003","journal-title":"Menopause"},{"key":"2019041122345660900_B5","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.steroids.2003.08.003","article-title":"All progestins are not created equal","volume":"68","author":"Stanczyk","year":"2003","journal-title":"Steroids"},{"key":"2019041122345660900_B6","first-page":"421","article-title":"Natural and synthetic female sex hormones","volume-title":"Reproductive endocrinology: physiology, pathophysiology and clinical management","author":"Henzl","year":"1978"},{"key":"2019041122345660900_B7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13697130500148875","article-title":"Pharmacology of estrogens and progestogens: influence of different routes of administration","volume":"8","author":"Kuhl","year":"2005","journal-title":"Climacteric"},{"key":"2019041122345660900_B8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0010-7824(90)90093-B","article-title":"Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids","volume":"42","author":"Stanczyk","year":"1990","journal-title":"Contraception"},{"key":"2019041122345660900_B9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0010-7824(99)00101-8","article-title":"Nomenclature of the gonane progestins","volume":"60","author":"Edgren","year":"1999","journal-title":"Contraception"},{"key":"2019041122345660900_B10","first-page":"393","article-title":"Pharmacokinetics of progesterone administered orally and parenterally","volume-title":"Progestins and antiprogestins in clinical practice","author":"Stanczyk","year":"2000"},{"key":"2019041122345660900_B11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0010-7824(97)00174-1","article-title":"In vivo conversion of norethesterone and norethisterone acetate to ethinyl estradiol in postmenopausal women","volume":"56","author":"Kuhnz","year":"1997","journal-title":"Contraception"},{"key":"2019041122345660900_B12","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1210\/jc.2007-0044","article-title":"Formation of ethinyl estradiol in women during treatment with norethindrone acetate","volume":"92","author":"Chu","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122345660900_B13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0022-4731(82)90629-X","article-title":"Distribution and percentage of non-protein bound contraceptive steroids in human serum","volume":"17","author":"Hammond","year":"1982","journal-title":"J Steroid Biochem"},{"key":"2019041122345660900_B14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0022-4731(90)90290-9","article-title":"Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum","volume":"35","author":"Kuhnz","year":"1990","journal-title":"J Steroid Biochem"},{"key":"2019041122345660900_B15","volume-title":"Steroid-protein interactions","author":"Westphal","year":"1974"},{"key":"2019041122345660900_B16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0015-0282(16)56031-2","article-title":"The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone","volume":"60","author":"Simon","year":"1993","journal-title":"Fertil Steril"},{"key":"2019041122345660900_B17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0010-7824(76)90099-8","article-title":"Pharmacokinetic observations on medroxyprogesterone acetate administered orally and intravaginally","volume":"14","author":"Victor","year":"1976","journal-title":"Contraception"},{"key":"2019041122345660900_B18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1081\/DDC-100101270","article-title":"Improved bioavailability of a micronized megestrol acetate tablet formulation in humans","volume":"26","author":"Farinha","year":"2000","journal-title":"Drug Dev Ind Pharm"},{"key":"2019041122345660900_B19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0010-7824(93)90118-Q","article-title":"Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles","volume":"48","author":"Kuhnz","year":"1993","journal-title":"Contraception"},{"key":"2019041122345660900_B20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0378-5122(90)90003-O","article-title":"Pharmacokinetics of oestrogens and progestogens","volume":"12","author":"Kuhl","year":"1990","journal-title":"Maturitas"},{"key":"2019041122345660900_B21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0378-4347(98)00223-0","article-title":"Determination of medrogestone in plasma by high-performance liquid chromatography","volume":"714","author":"Lin","year":"1998","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"2019041122345660900_B22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.steroids.2011.02.002","article-title":"Nomegestrol acetate, a novel progestogen for oral contraception","volume":"76","author":"Mueck","year":"2011","journal-title":"Steroids"},{"key":"2019041122345660900_B23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/cpt1978244448","article-title":"Kinetics of norethindrone in women. II. Single-dose kinetics","volume":"24","author":"Back","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"2019041122345660900_B24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0010-7824(81)90045-7","article-title":"The pharmacokinetics of levonorgestrel and ethynylestradiol in women: studies with Ovran and Ovranette","volume":"23","author":"Back","year":"1981","journal-title":"Contraception"},{"key":"2019041122345660900_B25","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/0002-9378(90)90553-J","article-title":"Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin","volume":"163","author":"Bergink","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"2019041122345660900_B26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0010-7824(87)80021-5","article-title":"Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel","volume":"35","author":"Back","year":"1987","journal-title":"Contraception"},{"key":"2019041122345660900_B27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0010-7824(91)90069-R","article-title":"The pharmacokinetics of ethinylestradiol in the presence and absence of gestodene and desogestrel","volume":"43","author":"Orme","year":"1991","journal-title":"Contraception"},{"key":"2019041122345660900_B28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0010-7824(89)90053-X","article-title":"Single dose pharmacokinetics of gestodene in women after intravenous and oral administration","volume":"40","author":"T\u00e4uber","year":"1989","journal-title":"Contraception"},{"key":"2019041122345660900_B29","first-page":"499","article-title":"A 19-norprogestin without a 17\u03b1-ethinyl group. II. Dienogest from a pharmacokinetic point of view","volume":"31","author":"Oettel","year":"1995","journal-title":"Drugs Today"},{"key":"2019041122345660900_B30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/13625180008500407","article-title":"A l-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers","volume":"5","author":"Blode","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"2019041122345660900_B31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone: pharmacology and pharmacokinetics of a unique progestogen","volume":"62","author":"Krattenmacher","year":"2000","journal-title":"Contraception"},{"key":"2019041122345660900_B32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/0002-9378(71)90686-7","article-title":"Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone","volume":"110","author":"Nillius","year":"1971","journal-title":"Am J Obstet Gynecol"},{"key":"2019041122345660900_B33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0015-0282(16)56935-0","article-title":"Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study","volume":"62","author":"Miles","year":"1994","journal-title":"Fertil Steril"},{"key":"2019041122345660900_B34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00042192-200512020-00019","article-title":"Percutaneous administration of progesterone: blood levels and endometrial protection","volume":"12","author":"Stanczyk","year":"2005","journal-title":"Menopause"},{"key":"2019041122345660900_B35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0015-0282(02)04542-9","article-title":"Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium","volume":"79","author":"Leonetti","year":"2003","journal-title":"Fertil Steril"},{"key":"2019041122345660900_B36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/13697130008500109","article-title":"Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women","volume":"3","author":"Wren","year":"2000","journal-title":"Climacteric"},{"key":"2019041122345660900_B37","volume-title":"Climara Pro","author":"Product insert","year":"2007"},{"key":"2019041122345660900_B38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/03639040600815178","article-title":"Simultaneous estradiol and levonorgestrel transdermal delivery from a 7-day patch: in vitro and in vivo drug deliveries of three formulations","volume":"33","author":"Harrison","year":"2007","journal-title":"Drug Dev Ind Pharm"},{"key":"2019041122345660900_B39","volume-title":"CombiPatch","author":"Product insert","year":"2006"},{"key":"2019041122345660900_B40","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/pr.58.4.9","article-title":"International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors","volume":"58","author":"Lu","year":"2006","journal-title":"Pharmacol Rev"},{"key":"2019041122345660900_B41","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.steroids.2011.03.001","article-title":"Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception","volume":"76","author":"Africander","year":"2011","journal-title":"Steroids"},{"key":"2019041122345660900_B42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mce.2011.09.019","article-title":"Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells","volume":"357","author":"Moore","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2019041122345660900_B43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/BJ20050872","article-title":"Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations","volume":"391","author":"Lavery","year":"2005","journal-title":"Biochem J"},{"key":"2019041122345660900_B44","doi-asserted-by":"crossref","first-page":"e003","DOI":"10.1621\/nrs.05003","article-title":"Visualizing the action of steroid hormone receptors in living cells","volume":"5","author":"Griekspoor","year":"2007","journal-title":"Nucl Recept Signal"},{"key":"2019041122345660900_B45","first-page":"1420","article-title":"The DNA-binding and \u03c42 transactivation domains of the rat glucocorticoid receptor constitute a nuclear matrix-targeting signal","volume":"12","author":"Tang","year":"1998","journal-title":"Mol Endocrinol"},{"key":"2019041122345660900_B46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0165-6147(00)01548-0","article-title":"Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications","volume":"21","author":"Bourguet","year":"2000","journal-title":"Trends Pharmacol Sci"},{"key":"2019041122345660900_B47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/humupd\/6.3.225","article-title":"Steroid hormone receptors: an update","volume":"6","author":"Beato","year":"2000","journal-title":"Hum Reprod Update"},{"key":"2019041122345660900_B48","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev.biochem.68.1.559","article-title":"Nuclear-receptor ligands and ligand-binding domains","volume":"68","author":"Weatherman","year":"1999","journal-title":"Ann Rev Biochem"},{"key":"2019041122345660900_B49","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1073\/pnas.95.11.5998","article-title":"Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains","volume":"95","author":"Tanenbaum","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041122345660900_B50","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/30775","article-title":"Atomic structure of progesterone complexed with its receptor","volume":"393","author":"Williams","year":"1998","journal-title":"Nature"},{"key":"2019041122345660900_B51","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1096\/fasebj.5.15.1743440","article-title":"The steroid receptor superfamily: mechanisms of diversity","volume":"5","author":"Fuller","year":"1991","journal-title":"FASEB J"},{"key":"2019041122345660900_B52","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1126\/science.3283939","article-title":"The steroid and thyroid hormone receptor superfamily","volume":"240","author":"Evans","year":"1988","journal-title":"Science"},{"key":"2019041122345660900_B53","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1073\/pnas.83.23.9045","article-title":"Cloning and sequence analysis of rabbit progesterone-receptor complementary DNA","volume":"83","author":"Loosfelt","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041122345660900_B54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0092-8674(02)00817-6","article-title":"Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition","volume":"110","author":"Bledsoe","year":"2002","journal-title":"Cell"},{"key":"2019041122345660900_B55","doi-asserted-by":"crossref","first-page":"12163","DOI":"10.1016\/S0021-9258(19)38326-7","article-title":"Transient expression of human and chicken progesterone receptors does not support alternative translational initiation from a single mRNA as the mechanism generating two receptor isoforms","volume":"265","author":"Kastner","year":"1990","journal-title":"J Biol Chem"},{"key":"2019041122345660900_B56","first-page":"1347","article-title":"A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform","volume":"8","author":"Sartorius","year":"1994","journal-title":"Mol Endocrinol"},{"key":"2019041122345660900_B57","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.1128\/MCB.14.12.8356","article-title":"The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells","volume":"14","author":"Wen","year":"1994","journal-title":"Mol Cell Biol"},{"key":"2019041122345660900_B58","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1128\/MCB.20.9.3102-3115.2000","article-title":"The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding","volume":"20","author":"Giangrande","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2019041122345660900_B59","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1074\/jbc.R110.179325","article-title":"Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids","volume":"286","author":"Oakley","year":"2011","journal-title":"J Biol Chem"},{"key":"2019041122345660900_B60","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.steroids.2005.02.006","article-title":"The human glucocorticoid receptor: one gene, multiple proteins and diverse responses","volume":"70","author":"Zhou","year":"2005","journal-title":"Steroids"},{"key":"2019041122345660900_B61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0960-0760(97)00119-2","article-title":"Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle","volume":"63","author":"Mangal","year":"1997","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2019041122345660900_B62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/gene.20098","article-title":"Cre-mediated recombination in cell lineages that express the progesterone receptor","volume":"41","author":"Soyal","year":"2005","journal-title":"Genesis"},{"key":"2019041122345660900_B63","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/endo-126-6-2882","article-title":"Developmental regulation of murine mammary progesterone receptor gene expression","volume":"126","author":"Shyamala","year":"1990","journal-title":"Endocrinology"},{"key":"2019041122345660900_B64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1530\/rep.1.00189","article-title":"Reproductive tissue selective actions of progesterone receptors","volume":"128","author":"Mulac-Jericevic","year":"2004","journal-title":"Reproduction"},{"key":"2019041122345660900_B65","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1210\/rp.57.1.339","article-title":"Reproductive functions of progesterone receptors","volume":"57","author":"Conneely","year":"2002","journal-title":"Recent Prog Horm Res"},{"key":"2019041122345660900_B66","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1210\/me.2011-1042","article-title":"p38 and p42\/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization","volume":"25","author":"Khan","year":"2011","journal-title":"Mol Endocrinol"},{"key":"2019041122345660900_B67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/1933719110382922","article-title":"Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing?","volume":"18","author":"Mesiano","year":"2011","journal-title":"Reprod Sci"},{"key":"2019041122345660900_B68","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI27987","article-title":"Estrogen receptors and human disease","volume":"116","author":"Deroo","year":"2006","journal-title":"J Clin Invest"},{"key":"2019041122345660900_B69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10549-011-1394-5","article-title":"Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells","volume":"131","author":"Courtin","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2019041122345660900_B70","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1073\/pnas.80.19.6056","article-title":"Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity","volume":"80","author":"Krozowski","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041122345660900_B71","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1046\/j.1523-1755.2000.00971.x","article-title":"Brain mineralocorticoid receptors and centrally regulated functions","volume":"57","author":"de Kloet","year":"2000","journal-title":"Kidney Int"},{"key":"2019041122345660900_B72","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.mce.2003.10.054","article-title":"Aldosterone, mineralocorticoid receptors and vascular inflammation","volume":"217","author":"Funder","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"2019041122345660900_B73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2005.07.001","article-title":"Synthetic progestogens used in HRT have different glucocorticoid agonist properties","volume":"242","author":"Koubovec","year":"2005","journal-title":"Mol Cell Endocrinol"},{"key":"2019041122345660900_B74","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/09513599909167574","article-title":"The pharmacological profile of a novel norpregnane progestin (trimegestone)","volume":"13","author":"Philibert","year":"1999","journal-title":"Gynecol Endocrinol"},{"key":"2019041122345660900_B75","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0010-7824(90)90039-X","article-title":"Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins","volume":"41","author":"Phillips","year":"1990","journal-title":"Contraception"},{"key":"2019041122345660900_B76","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0010-7824(93)90044-8","article-title":"Receptor binding of norgestimate: a new orally active synthetic progestational compound","volume":"47","author":"Juchem","year":"1993","journal-title":"Contraception"},{"key":"2019041122345660900_B77","first-page":"4055","article-title":"Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes","volume":"84","author":"Bamberger","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122345660900_B78","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/0022-4731(83)90371-0","article-title":"Binding of progestagens to receptor proteins in MCF-7 cells","volume":"19","author":"Bergink","year":"1983","journal-title":"J Steroid Biochem"},{"key":"2019041122345660900_B79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0960-0760(00)00093-5","article-title":"Influence of the substitution of 11-methylene, \u039415, and\/or 18-methyl groups in norethisterone on receptor binding, transactivation assays and biological activities in animals","volume":"74","author":"Deckers","year":"2000","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2019041122345660900_B80","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0022-4731(85)90151-7","article-title":"Stereospecificity of the intracellular binding of norethisterone and its A-ring reduced metabolites","volume":"22","author":"Ch\u00e1vez","year":"1985","journal-title":"J Steroid Biochem"},{"key":"2019041122345660900_B81","first-page":"2557","article-title":"Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer","volume":"40","author":"Teulings","year":"1980","journal-title":"Cancer Res"},{"key":"2019041122345660900_B82","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0960-0760(00)00125-4","article-title":"Hormonal properties of norethisterone, 7\u03b1-methyl-norethisterone and their derivatives","volume":"74","author":"Schoonen","year":"2000","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2019041122345660900_B83","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/mend.13.3.0255","article-title":"Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone","volume":"13","author":"Kemppainen","year":"1999","journal-title":"Mol Endocrinol"},{"key":"2019041122345660900_B84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0022-4731(81)90266-1","article-title":"Mechanism of action of contraceptive synthetic progestogens","volume":"15","author":"P\u00e9rez-Palacios","year":"1981","journal-title":"J Steroid Biochem"},{"key":"2019041122345660900_B85","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00689836","article-title":"Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor","volume":"25","author":"Hackenberg","year":"1993","journal-title":"Breast Cancer Res Treat"},{"key":"2019041122345660900_B86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0303-7207(99)00109-4","article-title":"Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells","volume":"154","author":"Bentel","year":"1999","journal-title":"Mol Cell Endocrinol"},{"key":"2019041122345660900_B87","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.maturitas.2003.09.014","article-title":"Classification and pharmacology of progestogens","volume":"46","author":"Schindler","year":"2003","journal-title":"Maturitas"},{"key":"2019041122345660900_B88","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.maturitas.2004.01.001","article-title":"Pharmacological profile of progestogens","volume":"47","author":"Sitruk-Ware","year":"2004","journal-title":"Maturitas"},{"key":"2019041122345660900_B89","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/0002-9378(90)90556-M","article-title":"Interactions with oral contraceptives","volume":"163","author":"Fotherby","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"2019041122345660900_B90","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0010-7824(96)00195-3","article-title":"The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential","volume":"54","author":"Fuhrmann","year":"1996","journal-title":"Contraception"},{"key":"2019041122345660900_B91","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1530\/acta.0.0920560","article-title":"Interaction of synthetic progestagens with renal mineralocorticoid receptors","volume":"92","author":"Wambach","year":"1979","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2019041122345660900_B92","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0960-0760(92)90430-Q","article-title":"Differences between aldosterone and its antagonists in binding kinetics and ligand-induced hsp90 release from mineralocorticosteroid receptor","volume":"41","author":"Rafestin-Oblin","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2019041122345660900_B93","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1081\/ERC-120016824","article-title":"Difference of in vivo and in vitro antimineralocorticoid potency of progesterone","volume":"28","author":"Quinkler","year":"2002","journal-title":"Endocr Res"},{"key":"2019041122345660900_B94","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/09513590701577869","article-title":"Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8\u20139, 2007","volume":"23","author":"Genazzani","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"2019041122345660900_B95","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0039-128X(03)00142-9","article-title":"The preclinical biology of a new potent and selective progestin: trimegestone","volume":"68","author":"Winneker","year":"2003","journal-title":"Steroids"},{"key":"2019041122345660900_B96","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.steroids.2003.08.008","article-title":"Conception and pharmacodynamic profile of drospirenone","volume":"68","author":"Elger","year":"2003","journal-title":"Steroids"},{"key":"2019041122345660900_B97","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.steroids.2007.10.003","article-title":"Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile","volume":"73","author":"Sasagawa","year":"2008","journal-title":"Steroids"},{"key":"2019041122345660900_B98","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mce.2004.03.006","article-title":"Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells","volume":"221","author":"Koubovec","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"2019041122345660900_B99","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.mce.2008.10.008","article-title":"Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction","volume":"299","author":"Ronacher","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"2019041122345660900_B100","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/0006-2952(83)90474-4","article-title":"Binding of progestogens to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes","volume":"32","author":"Kontula","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"2019041122345660900_B101","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0010-7824(94)00003-F","article-title":"Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays","volume":"51","author":"Fuhrmann","year":"1995","journal-title":"Contraception"},{"key":"2019041122345660900_B102","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1113\/jphysiol.1934.sp003217","article-title":"The assay of progestin","volume":"83","author":"McPhail","year":"1934","journal-title":"J Physiol"},{"key":"2019041122345660900_B103","first-page":"81","article-title":"Issues in animal pharmacology","volume-title":"Pharmacology of the contraceptive steroids","author":"Edgren","year":"1994"},{"key":"2019041122345660900_B104","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jsbmb.2005.06.032","article-title":"Quantitative analysis of gene regulation by seven clinically relevant progestogens suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells","volume":"97","author":"Bray","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2019041122345660900_B105","doi-asserted-by":"crossref","first-page":"R1036","DOI":"10.1186\/bcr1340","article-title":"The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells","volume":"7","author":"Ghatge","year":"2005","journal-title":"Breast Cancer Res"},{"key":"2019041122345660900_B106","first-page":"392","article-title":"Progestin regulation of vascular endothelial growth factor in human breast cancer cells","volume":"58","author":"Hyder","year":"1998","journal-title":"Cancer Res"},{"key":"2019041122345660900_B107","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0015-0282(02)04577-6","article-title":"Progestogens activate vascular endothelial growth factor gene transcription in endometrial adenocarcinoma cells","volume":"79","author":"Mueller","year":"2003","journal-title":"Fertil Steril"},{"key":"2019041122345660900_B108","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-2407-8-166","article-title":"Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion","volume":"8","author":"Fu","year":"2008","journal-title":"BMC Cancer"},{"key":"2019041122345660900_B109","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2165\/11532130-000000000-00000","article-title":"Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy","volume":"70","author":"Lello","year":"2010","journal-title":"Drugs"},{"key":"2019041122345660900_B110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.contraception.2010.11.017","article-title":"Nomegestrol acetate: steroid receptor transactivation profile in Chinese hamster ovary cells and ovulation inhibition in rat and monkey","volume":"84","author":"van Diepen","year":"2011","journal-title":"Contraception"},{"key":"2019041122345660900_B111","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1749-6632.1958.tb46801.x","article-title":"A new test of efficacy of progestational compounds","volume":"71","author":"Greenblatt","year":"1958","journal-title":"Ann NY Acad Sci"},{"key":"2019041122345660900_B112","first-page":"63","article-title":"Clinical assessment of relative potency of progestogens","volume":"5","author":"Swyer","year":"1968","journal-title":"J Reprod Fertil Suppl"},{"key":"2019041122345660900_B113","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0010-7824(85)90056-3","article-title":"Relative potency of progestins used in oral contraceptives","volume":"31","author":"Dorflinger","year":"1985","journal-title":"Contraception"},{"key":"2019041122345660900_B114","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJM198112313052701","article-title":"Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium","volume":"305","author":"Whitehead","year":"1981","journal-title":"N Engl J Med"},{"key":"2019041122345660900_B115","first-page":"539","article-title":"Effects of various types and dosages of progestins on the postmenopausal endometrium","volume":"27","author":"Whitehead","year":"1982","journal-title":"J Reprod Med"},{"key":"2019041122345660900_B116","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/bmj.287.6401.1241","article-title":"Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium","volume":"287","author":"Lane","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2019041122345660900_B117","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2007-1022574","article-title":"Avoidance of endometrial hyperstimulation in estrogen-treated postmenopausal women","volume":"1","author":"Whitehead","year":"1983","journal-title":"Semin Reprod Endocrinol"},{"key":"2019041122345660900_B118","first-page":"277","article-title":"The use of progestins and progesterone in the treatment of climacteric and postmenopausal symptoms","volume-title":"Progesterone and progestins","author":"Whitehead","year":"1983"},{"key":"2019041122345660900_B119","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1471-0528.1986.tb07814.x","article-title":"Effects of dydrogesterone on the oestrogenized postmenopausal endometrium","volume":"93","author":"Lane","year":"1986","journal-title":"Br J Obstet Gynaecol"},{"key":"2019041122345660900_B120","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0015-0282(16)49215-0","article-title":"Is Provera the ideal progestin for addition to postmenopausal estrogen therapy?","volume":"45","author":"Lane","year":"1986","journal-title":"Fertil Steril"},{"key":"2019041122345660900_B121","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0015-0282(16)49880-8","article-title":"Assessment of the potency of orally administered progestins in women","volume":"46","author":"King","year":"1986","journal-title":"Fertil Steril"},{"key":"2019041122345660900_B122","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1210\/me.2010-0027","article-title":"Role of kinases and chromatin remodeling in progesterone signaling to chromatin","volume":"24","author":"Vicent","year":"2010","journal-title":"Mol Endocrinol"},{"key":"2019041122345660900_B123","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.tem.2009.08.006","article-title":"Genome-wide mechanisms of nuclear receptor action","volume":"21","author":"Biddie","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"2019041122345660900_B124","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2004.09.057","article-title":"Progesterone receptor isoform identification and subcellular localization in endometrial cancer","volume":"96","author":"Leslie","year":"2005","journal-title":"Gynecol Oncol"},{"key":"2019041122345660900_B125","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1210\/mend.13.3.0247","article-title":"Differential localization and activity of the A- and B-forms of the human progesterone receptor using green fluorescent protein chimeras","volume":"13","author":"Lim","year":"1999","journal-title":"Mol Endocrinol"},{"key":"2019041122345660900_B126","first-page":"306","article-title":"Steroid receptor interactions with heat shock protein and immunophilin chaperones","volume":"18","author":"Pratt","year":"1997","journal-title":"Endocr Rev"},{"key":"2019041122345660900_B127","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/er.2007-0022","article-title":"Extranuclear steroid receptors: nature and actions","volume":"28","author":"Hammes","year":"2007","journal-title":"Endocr Rev"},{"key":"2019041122345660900_B128","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nrm1680","article-title":"Controlling nuclear receptors: the circular logic of cofactor cycles","volume":"6","author":"Perissi","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2019041122345660900_B129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0092-8674(89)90237-7","article-title":"Gene regulation by steroid hormones","volume":"56","author":"Beato","year":"1989","journal-title":"Cell"},{"key":"2019041122345660900_B130","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1128\/MCB.23.6.1994-2008.2003","article-title":"Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src\/Erk pathway in mammalian cells","volume":"23","author":"Ballar\u00e9","year":"2003","journal-title":"Mol Cell Biol"},{"key":"2019041122345660900_B131","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cell.2011.03.027","article-title":"Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor","volume":"145","author":"Surjit","year":"2011","journal-title":"Cell"},{"key":"2019041122345660900_B132","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.mce.2007.07.003","article-title":"Crosstalk between the glucocorticoid receptor and other transcription factors: Molecular aspects","volume":"275","author":"Kassel","year":"2007","journal-title":"Mol Cell Endocrinol"},{"key":"2019041122345660900_B133","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/me.2008-0283","article-title":"Minireview: latest perspectives on antiinflammatory actions of glucocorticoids","volume":"23","author":"De Bosscher","year":"2009","journal-title":"Mol Endocrinol"},{"key":"2019041122345660900_B134","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1152\/physrev.2001.81.4.1535","article-title":"Mechanisms of estrogen action","volume":"81","author":"Nilsson","year":"2001","journal-title":"Physiol Rev"},{"key":"2019041122345660900_B135","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1210\/er.2002-0006","article-title":"The interplay between the glucocorticoid receptor and nuclear factor-\u03baB or activator protein-1: molecular mechanisms for gene repression","volume":"24","author":"De Bosscher","year":"2003","journal-title":"Endocr Rev"},{"key":"2019041122345660900_B136","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1749-6632.2009.04986.x","article-title":"Mechanisms generating diversity in glucocorticoid receptor signaling","volume":"1179","author":"Revollo","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"2019041122345660900_B137","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1210\/me.2010-0289","article-title":"Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer","volume":"24","author":"Kobayashi","year":"2010","journal-title":"Mol Endocrinol"},{"key":"2019041122345660900_B138","first-page":"435","article-title":"Molecular control of immune\/inflammatory responses: interactions between nuclear factor-\u03baB and steroid receptor-signaling pathways","volume":"20","author":"McKay","year":"1999","journal-title":"Endocr Rev"},{"key":"2019041122345660900_B139","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1074\/jbc.271.11.6217","article-title":"Negative interaction between the RelA(p65) subunit of NF-\u03baB and the progesterone receptor","volume":"271","author":"Kalkhoven","year":"1996","journal-title":"J Biol Chem"},{"key":"2019041122345660900_B140","doi-asserted-by":"crossref","first-page":"24151","DOI":"10.1074\/jbc.271.39.24151","article-title":"Mutual transcriptional interference between RelA and androgen receptor","volume":"271","author":"Palvimo","year":"1996","journal-title":"J Biol Chem"},{"key":"2019041122345660900_B141","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1172\/JCI117995","article-title":"Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor","volume":"95","author":"Bellido","year":"1995","journal-title":"J Clin Invest"},{"key":"2019041122345660900_B142","doi-asserted-by":"crossref","first-page":"21467","DOI":"10.1074\/jbc.272.34.21467","article-title":"A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation","volume":"272","author":"Liden","year":"1997","journal-title":"J Biol Chem"},{"key":"2019041122345660900_B143","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1210\/me.2007-0437","article-title":"Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors","volume":"22","author":"Faivre","year":"2008","journal-title":"Mol Endocrinol"},{"key":"2019041122345660900_B144","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1128\/MCB.01539-06","article-title":"Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1\/2 mitogen-activated protein kinase in breast cancer cells","volume":"27","author":"Faivre","year":"2007","journal-title":"Mol Cell Biol"},{"key":"2019041122345660900_B145","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.mce.2011.01.004","article-title":"Progesterone induces expression of the prolactin receptor gene through cooperative action of Sp1 and C\/EBP","volume":"335","author":"Goldhar","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"2019041122345660900_B146","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.physiol.66.032802.154710","article-title":"Ligand control of coregulator recruitment to nuclear receptors","volume":"67","author":"Nettles","year":"2005","journal-title":"Annu Rev Physiol"},{"key":"2019041122345660900_B147","first-page":"321","article-title":"Nuclear receptor coregulators: cellular and molecular biology","volume":"20","author":"McKenna","year":"1999","journal-title":"Endocr Rev"},{"key":"2019041122345660900_B148","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/edrv.23.2.0460","article-title":"Androgen receptor (AR) coregulators: an overview","volume":"23","author":"Heinlein","year":"2002","journal-title":"Endocr Rev"},{"key":"2019041122345660900_B149","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1101\/gr.097022.109","article-title":"Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation","volume":"19","author":"Reddy","year":"2009","journal-title":"Genome Res"},{"key":"2019041122345660900_B150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ceb.2010.04.005","article-title":"3D shortcuts to gene regulation","volume":"22","author":"Hakim","year":"2010","journal-title":"Curr Opin Cell Biol"},{"key":"2019041122345660900_B151","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1371\/journal.pgen.0030136","article-title":"Identification and characterization of cell type-specific and ubiquitous chromatin regulatory structures in the human genome","volume":"3","author":"Xi","year":"2007","journal-title":"PLoS Genet"},{"key":"2019041122345660900_B152","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature07829","article-title":"Histone modifications at human enhancers reflect global cell-type-specific gene expression","volume":"459","author":"Heintzman","year":"2009","journal-title":"Nature"},{"key":"2019041122345660900_B153","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.tem.2010.11.004","article-title":"Negative regulation by nuclear receptors: a plethora of mechanisms","volume":"22","author":"Santos","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"2019041122345660900_B154","doi-asserted-by":"crossref","first-page":"19199","DOI":"10.1073\/pnas.0810634105","article-title":"Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules","volume":"105","author":"Hu","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041122345660900_B155","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","article-title":"Breast cancer and hormone-replacement therapy in the Million Women Study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"key":"2019041122345660900_B156","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/01.gme.0000196814.41871.ff","article-title":"Hormone therapy and breast cancer risk: trumping fear with facts","volume":"13","author":"Kaunitz","year":"2006","journal-title":"Menopause"},{"key":"2019041122345660900_B157","doi-asserted-by":"crossref","first-page":"909s","DOI":"10.1158\/1078-0432.909s.11.2","article-title":"Estrogen, estrogen plus progestin therapy, and risk of breast cancer","volume":"11","author":"Colditz","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2019041122345660900_B158","first-page":"248","article-title":"Comparative cardiovascular effects of different progestogens in menopause","volume":"46","author":"Rosano","year":"2001","journal-title":"Int J Fertil Womens Med"},{"key":"2019041122345660900_B159","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0039-128X(00)00174-4","article-title":"Progestins and cardiovascular risk markers","volume":"65","author":"Sitruk-Ware","year":"2000","journal-title":"Steroids"},{"key":"2019041122345660900_B160","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000292057","article-title":"Hormone replacement therapy affects various immune cell subsets and natural cytotoxicity","volume":"41","author":"Brunelli","year":"1996","journal-title":"Gynecol Obstet Invest"},{"key":"2019041122345660900_B161","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02778145","article-title":"Differential effects of estrogen and medroxyprogesterone on basal and stress-induced growth hormone release, IGF-1 levels, and cellular immunity in postmenopausal women","volume":"7","author":"Malarkey","year":"1997","journal-title":"Endocrine"},{"key":"2019041122345660900_B162","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/hc1202.105945","article-title":"Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen","volume":"105","author":"Wakatsuki","year":"2002","journal-title":"Circulation"},{"key":"2019041122345660900_B163","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jri.2005.07.006","article-title":"Effect of estrogen\/progesterone hormone replacement therapy on natural killer cell cytotoxicity and immunoregulatory cytokine release by peripheral blood mononuclear cells of postmenopausal women","volume":"69","author":"Stopi\u0144ska-G\u0142uszak","year":"2006","journal-title":"J Reprod Immunol"},{"key":"2019041122345660900_B164","first-page":"99","article-title":"Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports","volume":"6","author":"Ohkura","year":"1995","journal-title":"Dementia"},{"key":"2019041122345660900_B165","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/jama.289.20.2651","article-title":"Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial","volume":"289","author":"Shumaker","year":"2003","journal-title":"JAMA"},{"key":"2019041122345660900_B166","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.fertnstert.2003.07.041","article-title":"Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women","volume":"81","author":"Valdivia","year":"2004","journal-title":"Fertil Steril"},{"key":"2019041122345660900_B167","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/09513590410001667265","article-title":"Long-term effects of two different continuous combined regimens of hormone replacement therapy on well-being","volume":"18","author":"Odmark","year":"2004","journal-title":"Gynecol Endocrinol"},{"key":"2019041122345660900_B168","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mce.2003.10.030","article-title":"Drospirenone, a progestogen with antimineralocorticoid properties: a short review","volume":"217","author":"Oelkers","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"2019041122345660900_B169","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1210\/en.2010-0005","article-title":"Clinically relevant progestins regulate neurogenic and neuroprotective responses in vitro and in vivo","volume":"151","author":"Liu","year":"2010","journal-title":"Endocrinology"},{"key":"2019041122345660900_B170","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1210\/jcem.87.6.8526","article-title":"Long-term progestin treatment inhibits RANTES (regulated on activation, normal T cell expressed and secreted) gene expression in human endometrial stromal cells","volume":"87","author":"Zhao","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122345660900_B171","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1600-0897.2006.00430.x","article-title":"Induction of maternal tolerance to fetalalloantigens by RANTES production","volume":"56","author":"Ramhorst","year":"2006","journal-title":"Am J Reprod Immunol"},{"key":"2019041122345660900_B172","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0378-5122(02)00157-3","article-title":"Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestogens","volume":"42","author":"Tatsumi","year":"2002","journal-title":"Maturitas"},{"key":"2019041122345660900_B173","first-page":"41","article-title":"Vasoprotective effects of nitric oxide in atherosclerosis","volume":"30","author":"Yasa","year":"2005","journal-title":"FABAD J Pharm Sci"},{"key":"2019041122345660900_B174","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1210\/en.2004-0510","article-title":"Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells","volume":"145","author":"Simoncini","year":"2004","journal-title":"Endocrinology"},{"key":"2019041122345660900_B175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09513590701585094","article-title":"Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels","volume":"23","author":"Simoncini","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"2019041122345660900_B176","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1210\/en.2010-1061","article-title":"Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function","volume":"152","author":"Irwin","year":"2011","journal-title":"Endocrinology"},{"key":"2019041122345660900_B177","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1196\/annals.1290.033","article-title":"Androgens and antiandrogens","volume":"997","author":"Schneider","year":"2003","journal-title":"Ann NY Acad Sci"},{"key":"2019041122345660900_B178","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1749-6632.1995.tb31386.x","article-title":"Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity","volume":"761","author":"Muhn","year":"1995","journal-title":"Ann NY Acad Sci"},{"key":"2019041122345660900_B179","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0039-128X(00)00120-3","article-title":"In vitro characterization of trimegestone: a new potent and selective progestin","volume":"65","author":"Zhang","year":"2000","journal-title":"Steroids"},{"key":"2019041122345660900_B180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jsbmb.2004.02.003","article-title":"Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestogens","volume":"91","author":"Garc\u00eda-Becerra","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2019041122345660900_B181","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.contraception.2011.06.006","article-title":"Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract","volume":"84","author":"Africander","year":"2011","journal-title":"Contraception"},{"key":"2019041122345660900_B182","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1096\/fj.06-7518com","article-title":"Disruption of androgen receptor signaling by synthetic progestogens may increase risk of developing breast cancer","volume":"21","author":"Birrell","year":"2007","journal-title":"FASEB J"},{"key":"2019041122345660900_B183","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.steroids.2011.05.007","article-title":"Differential nuclear localisation and promoter occupancy play a role in glucocorticoid receptor ligand-specific transcriptional responses","volume":"76","author":"Hadley","year":"2011","journal-title":"Steroids"},{"key":"2019041122345660900_B184","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s001980200080","article-title":"Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis","volume":"13","author":"Ishida","year":"2002","journal-title":"Osteoporos Int"},{"key":"2019041122345660900_B185","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2265.2007.03059.x","article-title":"Effect of progestogens with different glucocorticoid activity on bone metabolism","volume":"68","author":"Ishida","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122345660900_B186","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/105072503321582042","article-title":"Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2","volume":"13","author":"Kurebayashi","year":"2003","journal-title":"Thyroid"},{"key":"2019041122345660900_B187","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.intimp.2003.08.005","article-title":"Receptor density dictates the behavior of a subset of steroid ligands in glucocorticoid receptor-mediated transrepression","volume":"3","author":"Zhao","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"2019041122345660900_B188","doi-asserted-by":"crossref","first-page":"F306","DOI":"10.1152\/ajprenal.00062.2005","article-title":"Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate \u03b1-ENaC and sgk1 expression in renal collecting duct epithelia","volume":"290","author":"Thomas","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"2019041122345660900_B189","first-page":"3763","article-title":"Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds","volume":"9","author":"Ouatas","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2019041122345660900_B190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1096\/fj.06-6840com","article-title":"Progestogens overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors","volume":"21","author":"Zerr-Fouineau","year":"2007","journal-title":"FASEB J"},{"key":"2019041122345660900_B191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/frne.1995.1001","article-title":"Role of the cytokines in the neuroendocrine-immune system axis","volume":"16","author":"Spangelo","year":"1995","journal-title":"Front Neuroendocrinol"},{"key":"2019041122345660900_B192","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1096\/fj.01-0245com","article-title":"Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells","volume":"16","author":"Galon","year":"2002","journal-title":"FASEB J"},{"key":"2019041122345660900_B193","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1161\/hc4801.099737","article-title":"Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor","volume":"104","author":"Herkert","year":"2001","journal-title":"Circulation"},{"key":"2019041122345660900_B194","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1582-4934.2007.00177.x","article-title":"The glucocorticoid receptor signalling in breast cancer","volume":"12","author":"Moutsatsou","year":"2008","journal-title":"J Cell Mol Med"},{"key":"2019041122345660900_B195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10549-011-1394-5","article-title":"Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells","volume":"131","author":"Courtin","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2019041122345660900_B196","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1210\/mend.16.6.0848","article-title":"Overlapping but distinct gene regulation profiles by glucocorticoids and progestins in human breast cancer cells","volume":"16","author":"Wan","year":"2002","journal-title":"Mol Endocrinol"},{"key":"2019041122345660900_B197","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0039-128X(96)00007-4","article-title":"Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure","volume":"61","author":"Oelkers","year":"1996","journal-title":"Steroids"},{"key":"2019041122345660900_B198","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.290.6461.13","article-title":"Natural progesterone and antihypertensive action","volume":"290","author":"Rylance","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2019041122345660900_B199","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1530\/eje.0.1460789","article-title":"Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor","volume":"146","author":"Quinkler","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2019041122345660900_B200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13697130500330341","article-title":"Drospirenone in combination with estrogens: for contraception and hormone replacement therapy","volume":"8","author":"Oelkers","year":"2005","journal-title":"Climacteric"},{"key":"2019041122345660900_B201","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1177\/0192623309350475","article-title":"Differential effects of 17\u03b2-estradiol and of synthetic progestogens on aldosterone-salt-induced kidney disease","volume":"37","author":"Arias-Loza","year":"2009","journal-title":"Toxicol Pathol"},{"key":"2019041122345660900_B202","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/13697130802403994","article-title":"Effects of drospirenone on cardiovascular markers in human aortic endothelial cells","volume":"12","author":"Seeger","year":"2009","journal-title":"Climacteric"},{"key":"2019041122345660900_B203","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1677\/joe.0.0980385","article-title":"Changes in the binding of oestradiol to uterine oestrogen receptors induced by some progesterone and 19-nor-testosterone derivatives","volume":"98","author":"Di Carlo","year":"1983","journal-title":"J Endocrinol"},{"key":"2019041122345660900_B204","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0960-0760(94)90254-2","article-title":"Estrogenic and progestagenic activities coexisting in steroidal drugs: quantitative evaluation by in vitro bioassays with human cells","volume":"48","author":"Markiewicz","year":"1994","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2019041122345660900_B205","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0010-7824(99)00039-6","article-title":"Variations of progesterone receptor and c-fos gene expression in the rat uterus after treatment with norethisterone and its A-ring reduced metabolites","volume":"59","author":"Mendoza-Rodr\u00edguez","year":"1999","journal-title":"Contraception"},{"key":"2019041122345660900_B206","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1210\/endo.142.9.8401","article-title":"A-ring reduced metabolites of 19-nor synthetic progestogens as subtype selective agonists for ER\u03b1","volume":"142","author":"Larrea","year":"2001","journal-title":"Endocrinology"},{"key":"2019041122345660900_B207","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1513\/pats.200402-015MS","article-title":"Post-transcriptional and nongenomic effects of glucocorticoids","volume":"1","author":"Stellato","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"2019041122345660900_B208","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1152\/advan.00086.2006","article-title":"Sex steroid effects at target tissues: mechanisms of action","volume":"31","author":"Wierman","year":"2007","journal-title":"Adv Physiol Educ"},{"key":"2019041122345660900_B209","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mce.2009.02.005","article-title":"New aspects of rapid aldosterone signaling","volume":"308","author":"Grossmann","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"2019041122345660900_B210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cbpc.2008.05.019","article-title":"Candidates for membrane progestin receptors: past approaches and future challenges","volume":"148","author":"Zhu","year":"2008","journal-title":"Comp Biochem Physiol C Toxicol Pharmacol"},{"key":"2019041122345660900_B211","doi-asserted-by":"crossref","first-page":"10506","DOI":"10.1073\/pnas.1334098100","article-title":"Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling","volume":"100","author":"Nilsen","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041122345660900_B212","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.steroids.2008.01.010","article-title":"The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression","volume":"73","author":"Boonyaratanakornkit","year":"2008","journal-title":"Steroids"},{"key":"2019041122345660900_B213","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mce.2011.09.017","article-title":"Role of phosphorylation in progesterone receptor signaling and specificity","volume":"357","author":"Hagan","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2019041122345660900_B214","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1128\/MCB.25.12.4826-4840.2005","article-title":"Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells","volume":"25","author":"Proietti","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2019041122345660900_B215","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1128\/MCB.00012-10","article-title":"Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3","volume":"30","author":"B\u00e9guelin","year":"2010","journal-title":"Mol Cell Biol"},{"key":"2019041122345660900_B216","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.yfrne.2008.01.001","article-title":"Characteristics of membrane progestin receptor \u03b1 (mPR\u03b1) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions","volume":"29","author":"Thomas","year":"2008","journal-title":"Front Neuroendocrinol"},{"key":"2019041122345660900_B217","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1210\/en.2006-0974","article-title":"Steroid and G protein binding characteristics of the sea trout and human progestin membrane receptor \u03b1 subtypes and their evolutionary origins","volume":"148","author":"Thomas","year":"2007","journal-title":"Endocrinology"},{"key":"2019041122345660900_B218","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1677\/JOE-07-0317","article-title":"Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone","volume":"196","author":"Dosiou","year":"2008","journal-title":"J Endocrinol"},{"key":"2019041122345660900_B219","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1210\/en.2004-1535","article-title":"Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase\/Akt\/nuclear factor-\u03baB cascade in human breast cancer cells","volume":"146","author":"Saitoh","year":"2005","journal-title":"Endocrinology"},{"key":"2019041122345660900_B220","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI0215481","article-title":"Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids","volume":"110","author":"Limbourg","year":"2002","journal-title":"J Clin Invest"},{"key":"2019041122345660900_B221","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000111559","article-title":"Rapid estrogen signaling in the brain","volume":"16","author":"Raz","year":"2008","journal-title":"Neurosignals"},{"key":"2019041122345660900_B222","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0070-2153(03)01006-8","article-title":"Nongenomic actions of androgen in Sertoli cells","volume":"56","author":"Walker","year":"2003","journal-title":"Curr Top Dev Biol"},{"key":"2019041122345660900_B223","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1016\/j.contraception.2006.12.011","article-title":"United States regulatory considerations for intrauterine progestins for hormone replacement therapy","volume":"75","author":"Rarick","year":"2007","journal-title":"Contraception"},{"key":"2019041122345660900_B224","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/archinte.1997.00440430091011","article-title":"Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab\/Osteoporosis Study Group","volume":"157","author":"Genant","year":"1997","journal-title":"Arch Intern Med"},{"key":"2019041122345660900_B225","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/01.AOG.0000137833.43248.79","article-title":"Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial","volume":"104","author":"Ettinger","year":"2004","journal-title":"Obstet Gynecol"},{"key":"2019041122345660900_B226","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","article-title":"Endometrial cancer and hormone-replacement therapy in the Million Women Study","volume":"365","author":"Beral","year":"2005","journal-title":"Lancet"},{"key":"2019041122345660900_B227","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.1996.03530290040035","article-title":"Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen\/Progestin Interventions (PEPI) Trial","volume":"275","author":"The Writing Group for the PEPI Trial","year":"1996","journal-title":"JAMA"},{"key":"2019041122345660900_B228","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/aje\/kwq300","article-title":"Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition","volume":"172","author":"Allen","year":"2010","journal-title":"Am J Epidemiol"},{"key":"2019041122345660900_B229","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mob.2002.124941","article-title":"Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study","volume":"187","author":"Cicinelli","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"2019041122345660900_B230","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.fertnstert.2005.01.095","article-title":"Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study","volume":"83","author":"Cicinelli","year":"2005","journal-title":"Fertil Steril"},{"key":"2019041122345660900_B231","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1093\/humrep\/dei085","article-title":"Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women","volume":"20","author":"Hampton","year":"2005","journal-title":"Hum Reprod"},{"key":"2019041122345660900_B232","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0015-0282(99)00162-4","article-title":"The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience","volume":"72","author":"Suvanto-Luukkonen","year":"1999","journal-title":"Fertil Steril"},{"key":"2019041122345660900_B233","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0015-0282(01)02846-1","article-title":"A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy","volume":"76","author":"Varila","year":"2001","journal-title":"Fertil Steril"},{"key":"2019041122345660900_B234","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jsbmb.2007.12.002","article-title":"Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause?","volume":"109","author":"Seeger","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2019041122345660900_B235","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.295.14.1647","article-title":"Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy","volume":"295","author":"Stefanick","year":"2006","journal-title":"JAMA"},{"key":"2019041122345660900_B236","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/jama.2010.1500","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women","volume":"304","author":"Chlebowski","year":"2010","journal-title":"JAMA"},{"key":"2019041122345660900_B237","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","article-title":"Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial","volume":"289","author":"Chlebowski","year":"2003","journal-title":"JAMA"},{"key":"2019041122345660900_B238","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-130-4_Part_1-199902160-00003","article-title":"Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen\/Progestin Interventions (PEPI) Investigators","volume":"130","author":"Greendale","year":"1999","journal-title":"Ann Intern Med"},{"key":"2019041122345660900_B239","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/13697130701385805","article-title":"Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density","volume":"10","author":"Lundstr\u00f6m","year":"2007","journal-title":"Climacteric"},{"key":"2019041122345660900_B240","first-page":"1148","article-title":"Hormone replacement therapy regimens and breast cancer risk (1)","volume":"100","author":"Weiss","year":"2002","journal-title":"Obstet Gynecol"},{"key":"2019041122345660900_B241","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/cncr.11205","article-title":"Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden","volume":"97","author":"Olsson","year":"2003","journal-title":"Cancer"},{"key":"2019041122345660900_B242","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/jnci\/92.4.328","article-title":"Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin","volume":"92","author":"Ross","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2019041122345660900_B243","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/jama.283.4.485","article-title":"Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk","volume":"283","author":"Schairer","year":"2000","journal-title":"JAMA"},{"key":"2019041122345660900_B244","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1001\/jama.289.24.3254","article-title":"Relationship between long durations and different regimens of hormone therapy and risk of breast cancer","volume":"289","author":"Li","year":"2003","journal-title":"JAMA"},{"key":"2019041122345660900_B245","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/jama.287.6.734","article-title":"Hormone replacement therapy in relation to breast cancer","volume":"287","author":"Chen","year":"2002","journal-title":"JAMA"},{"key":"2019041122345660900_B246","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/AOG.0b013e31818fdde4","article-title":"Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer","volume":"113","author":"Jick","year":"2009","journal-title":"Obstet Gynecol"},{"key":"2019041122345660900_B247","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1200\/JCO.2003.05.151","article-title":"Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population","volume":"21","author":"Kerlikowske","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019041122345660900_B248","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/humupd\/dmi028","article-title":"Breast cancer risk with postmenopausal hormonal treatment","volume":"11","author":"Collins","year":"2005","journal-title":"Hum Reprod Update"},{"key":"2019041122345660900_B249","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/cncr.24101","article-title":"Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype","volume":"115","author":"Calle","year":"2009","journal-title":"Cancer"},{"key":"2019041122345660900_B250","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(12)70075-X","article-title":"Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial","volume":"13","author":"Anderson","year":"2012","journal-title":"Lancet Oncol"},{"key":"2019041122345660900_B251","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/jnci\/djs014","article-title":"Changing concepts: menopausal hormone therapy and breast cancer","volume":"104","author":"Chlebowski","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2019041122345660900_B252","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(05)66431-8","article-title":"Hormones and endometrial cancer\u2013new data from the Million Women Study","volume":"365","author":"Brinton","year":"2005","journal-title":"Lancet"},{"key":"2019041122345660900_B253","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ijc.20710","article-title":"Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort","volume":"114","author":"Fournier","year":"2005","journal-title":"Int J Cancer"},{"key":"2019041122345660900_B254","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMsr070105","article-title":"The decrease in breast-cancer incidence in 2003 in the United States","volume":"356","author":"Ravdin","year":"2007","journal-title":"N Engl J Med"},{"key":"2019041122345660900_B255","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.288.1.49","article-title":"Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II)","volume":"288","author":"Grady","year":"2002","journal-title":"JAMA"},{"key":"2019041122345660900_B256","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"2019041122345660900_B257","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"key":"2019041122345660900_B258","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/13697130903012306","article-title":"Cardiovascular aspects of menopausal hormone replacement therapy","volume":"12","author":"Rosano","year":"2009","journal-title":"Climacteric"},{"key":"2019041122345660900_B259","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ncpcardio1234","article-title":"Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity?","volume":"5","author":"Hermsmeyer","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"2019041122345660900_B260","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.1995.03520270033028","article-title":"Effects of estrogen or estrogen\/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen\/progestin interventions (PEPI) trial","volume":"273","author":"Writing Group for the PEPI Trial","year":"1995","journal-title":"JAMA"},{"key":"2019041122345660900_B261","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/S0735-1097(00)01007-X","article-title":"Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women","volume":"36","author":"Rosano","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2019041122345660900_B262","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1210\/jc.2004-1557","article-title":"Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys","volume":"90","author":"Mishra","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122345660900_B263","first-page":"H2645","article-title":"Ca2+ release mechanism of primate drug-induced coronary vasospasm","volume":"272","author":"Miyagawa","year":"1997","journal-title":"Am J Physiol"},{"key":"2019041122345660900_B264","first-page":"649","article-title":"Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys","volume":"83","author":"Minshall","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122345660900_B265","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.ATV.0000126372.14332.70","article-title":"Prevention of coronary hyperreactivity in pre-atherogenic menopausal rhesus monkeys by transdermal progesterone","volume":"24","author":"Hermsmeyer","year":"2004","journal-title":"Arteriosclerosis Thromb Vasc Biol"},{"key":"2019041122345660900_B266","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0026-0495(96)90244-9","article-title":"The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys","volume":"45","author":"Wagner","year":"1996","journal-title":"Metabolism"},{"key":"2019041122345660900_B267","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.maturitas.2005.10.004","article-title":"Which progestogen is more likely to increase the risk of fatal myocardial infarction: a combination of epidemiological and trial evidence","volume":"54","author":"Al-Azzawi","year":"2006","journal-title":"Maturitas"},{"key":"2019041122345660900_B268","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0015-0282(01)01699-5","article-title":"Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974\u20132000","volume":"75","author":"Godsland","year":"2001","journal-title":"Fertil Steril"},{"key":"2019041122345660900_B269","doi-asserted-by":"crossref","first-page":"47E","DOI":"10.1016\/S0002-9149(02)02413-X","article-title":"Effects of progestins in different hormone replacement therapy formulations on estrogen-induced lipid changes in postmenopausal women","volume":"89","author":"Shulman","year":"2002","journal-title":"Am J Cardiol"},{"key":"2019041122345660900_B270","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1160\/TH07-12-0746","article-title":"Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)\/dydrogesterone and estradiol (2 mg)\/trimegestone","volume":"100","author":"Norris","year":"2008","journal-title":"Thromb Haemost"},{"key":"2019041122345660900_B271","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/gme.0b013e3181e102eb","article-title":"Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen","volume":"17","author":"Canonico","year":"2010","journal-title":"Menopause"},{"key":"2019041122345660900_B272","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/ATVBAHA.109.196022","article-title":"Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study","volume":"30","author":"Canonico","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2019041122345660900_B273","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.maturitas.2005.05.006","article-title":"Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels","volume":"53","author":"Gol","year":"2006","journal-title":"Maturitas"},{"key":"2019041122345660900_B274","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/01.CIR.103.15.1961","article-title":"Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women","volume":"103","author":"Koh","year":"2001","journal-title":"Circulation"},{"key":"2019041122345660900_B275","first-page":"388","article-title":"Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite\/nitrate) levels in postmenopausal women substituted with 17\u03b2-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate","volume":"82","author":"Imthurn","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122345660900_B276","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000232179.60442.84","article-title":"Effects of a new hormone therapy, drospirenone and 17-\u03b2-estradiol, in postmenopausal women with hypertension","volume":"48","author":"White","year":"2006","journal-title":"Hypertension"},{"key":"2019041122345660900_B277","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jash.2007.08.004","article-title":"Effects of the hormone therapy, drospirenone and 17-\u03b2 estradiol, on early morning blood pressure in postmenopausal women with hypertension","volume":"2","author":"White","year":"2008","journal-title":"J Am Soc Hypertens"},{"key":"2019041122345660900_B278","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/13697130903437375","article-title":"A review of the cardiovascular and breast actions of drospirenone in preclinical studies","volume":"13","author":"Simoncini","year":"2010","journal-title":"Climacteric"},{"key":"2019041122345660900_B279","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/13697130902780853","article-title":"Risk of cardiovascular outcomes in users of estradiol\/dydrogesterone or other HRT preparations","volume":"12","author":"Schneider","year":"2009","journal-title":"Climacteric"},{"key":"2019041122345660900_B280","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"key":"2019041122345660900_B281","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1001\/archinte.164.18.1965","article-title":"Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review","volume":"164","author":"Gomes","year":"2004","journal-title":"Arch Intern Med"},{"key":"2019041122345660900_B282","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1345\/aph.1M649","article-title":"Risk of venous thromboembolism with drospirenone in combined oral contraceptive products","volume":"44","author":"Sehovic","year":"2010","journal-title":"Ann Pharmacother"},{"key":"2019041122345660900_B283","doi-asserted-by":"crossref","first-page":"d2139","DOI":"10.1136\/bmj.d2139","article-title":"Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database","volume":"342","author":"Parkin","year":"2011","journal-title":"BMJ"},{"key":"2019041122345660900_B284","doi-asserted-by":"crossref","first-page":"d2151","DOI":"10.1136\/bmj.d2151","article-title":"Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data","volume":"342","author":"Jick","year":"2011","journal-title":"BMJ"},{"key":"2019041122345660900_B285","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"2011 Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"2019041122345660900_B286","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1210\/en.2007-1592","article-title":"Progesterone biosynthesis and action in the developing neuron","volume":"149","author":"Tsutsui","year":"2008","journal-title":"Endocrinology"},{"key":"2019041122345660900_B287","first-page":"95","article-title":"Progestins and neuroprotection: are all progestins created equal?","volume":"32","author":"Singh","year":"2007","journal-title":"Minerva Endocrinol"},{"key":"2019041122345660900_B288","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.annemergmed.2006.07.932","article-title":"ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury","volume":"49","author":"Wright","year":"2007","journal-title":"Ann Emerg Med"},{"key":"2019041122345660900_B289","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/cc6887","article-title":"Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial","volume":"12","author":"Xiao","year":"2008","journal-title":"Crit Care"},{"key":"2019041122345660900_B290","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2174\/092986709787846523","article-title":"Exogenous progesterone: a potential therapeutic candidate in CNS injury and neurodegeneration","volume":"16","author":"Hu","year":"2009","journal-title":"Curr Med Chem"},{"key":"2019041122345660900_B291","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1517\/13543784.2010.489549","article-title":"Progesterone in the clinical treatment of acute traumatic brain injury","volume":"19","author":"Stein","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"2019041122345660900_B292","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.coph.2008.10.002","article-title":"Progesterone and progestins: neuroprotection and myelin repair","volume":"8","author":"Schumacher","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"2019041122345660900_B293","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/neu.20293","article-title":"Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective","volume":"66","author":"Ciriza","year":"2006","journal-title":"J Neurobiol"},{"key":"2019041122345660900_B294","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1385\/ENDO:29:2:271","article-title":"Progesterone-induced neuroprotection","volume":"29","author":"Singh","year":"2006","journal-title":"Endocrine"},{"key":"2019041122345660900_B295","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1210\/endo.143.1.8582","article-title":"Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate","volume":"143","author":"Nilsen","year":"2002","journal-title":"Endocrinology"},{"key":"2019041122345660900_B296","doi-asserted-by":"crossref","first-page":"10506","DOI":"10.1073\/pnas.1334098100","article-title":"Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling","volume":"100","author":"Nilsen","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041122345660900_B297","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/09513590600863337","article-title":"Medroxyprogesterone acetate exacerbates glutamate excitotoxicity","volume":"22","author":"Nilsen","year":"2006","journal-title":"Gynecol Endocrinol"},{"key":"2019041122345660900_B298","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/02699050701867399","article-title":"Effects of medroxyprogesterone acetate on cerebral oedema and spatial learning performance after traumatic brain injury in rats","volume":"22","author":"Wright","year":"2008","journal-title":"Brain Inj"},{"key":"2019041122345660900_B299","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1212\/01.wnl.0000339037.76336.cf","article-title":"Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study","volume":"72","author":"Resnick","year":"2009","journal-title":"Neurology"},{"key":"2019041122345660900_B300","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1210\/er.2006-0050","article-title":"Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system","volume":"28","author":"Schumacher","year":"2007","journal-title":"Endocr Rev"},{"key":"2019041122345660900_B301","unstructured":"Nelson HD 2002 Hormone replacement therapy and osteoporosis. Systematic Evidence Reviews No. 12. Rockville, MD: Agency for Healthcare Research and Quality. http:\/\/www.ncbi.nlm.nih.gov\/bookshelf\/br.fcgi?book=es12"},{"key":"2019041122345660900_B302","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/humrep\/deg315","article-title":"Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis","volume":"18","author":"D\u00f6ren","year":"2003","journal-title":"Hum Reprod"},{"key":"2019041122345660900_B303","first-page":"789","article-title":"Prevention of bone mineral loss in postmenopausal women by norethisterone","volume":"66","author":"Abdalla","year":"1985","journal-title":"Obstet Gynecol"},{"key":"2019041122345660900_B304","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9343(91)90538-9","article-title":"Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen","volume":"90","author":"Gallagher","year":"1991","journal-title":"Am J Med"},{"key":"2019041122345660900_B305","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0002-9343(94)90092-2","article-title":"Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances","volume":"96","author":"Prior","year":"1994","journal-title":"Am J Med"},{"key":"2019041122345660900_B306","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.ajog.2005.10.201","article-title":"Unsuccessful attempt to demonstrate progesterone's bone formation actions","volume":"194","author":"Prior","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"2019041122345660900_B307","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0889-8545(02)00008-6","article-title":"Access of reproductive steroids to target tissues","volume":"29","author":"Hammond","year":"2002","journal-title":"Obstet Gynecol Clin North Am"},{"key":"2019041122345660900_B308","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.maturitas.2007.02.015","article-title":"Routes of delivery for progesterone and progestogens","volume":"57","author":"Sitruk-Ware","year":"2007","journal-title":"Maturitas"},{"key":"2019041122345660900_B309","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/13697130500330382","article-title":"Pharmacology of different progestogens: the special case of drospirenone","volume":"8","author":"Sitruk-Ware","year":"2005","journal-title":"Climacteric"},{"key":"2019041122345660900_B310","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.contraception.2005.08.019","article-title":"Contraception: an international perspective","volume":"73","author":"Sitruk-Ware","year":"2006","journal-title":"Contraception"},{"key":"2019041122345660900_B311","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12672-010-0023-9","article-title":"Expression of membrane progesterone receptors (mPR\/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events","volume":"1","author":"Charles","year":"2010","journal-title":"Horm Cancer"},{"key":"2019041122345660900_B312","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1126\/science.1068537","article-title":"Molecular determinants for the tissue specificity of SERMs","volume":"295","author":"Shang","year":"2002","journal-title":"Science"},{"key":"2019041122345660900_B313","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X","article-title":"The behavior of endometrial hyperplasia. A long-term study of \u201cuntreated\u201d hyperplasia in 170 patients","volume":"56","author":"Kurman","year":"1985","journal-title":"Cancer"},{"key":"2019041122345660900_B314","unstructured":"Africander D 2010 Comparative study of the molecular mechanism of action of the synthetic progestins, MPA and norethisterone acetate. PhD thesis, University of Stellenbosch, South Africa"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/34\/2\/171\/8858564\/edrv0171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T17:13:51Z","timestamp":1688145231000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/34\/2\/171\/2354628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,13]]},"references-count":314,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,12,13]]},"published-print":{"date-parts":[[2013,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/er.2012-1008","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,13]]}}}